Provided by Tiger Trade Technology Pte. Ltd.

PagerDuty, Inc.

6.01
-0.3000-4.75%
Post-market: 6.030.0200+0.33%19:55 EDT
Volume:2.51M
Turnover:15.15M
Market Cap:510.73M
PE:3.21
High:6.25
Open:6.21
Low:5.92
Close:6.31
52wk High:18.97
52wk Low:5.92
Shares:84.98M
Float Shares:80.63M
Volume Ratio:0.85
T/O Rate:3.12%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.87
EPS(LYR):1.87
ROE:82.50%
ROA:0.48%
PB:2.01
PE(LYR):3.21

Loading ...

Press Release: PagerDuty to Report Third Quarter Fiscal Year 2026 Results on November 25, 2025

Dow Jones
·
Nov 12, 2025

Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

GlobeNewswire
·
Nov 11, 2025

Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

GlobeNewswire
·
Nov 07, 2025

Immunocore presents Phase 1 data for hepatitis B candidate at AASLD’s The Liver Meeting

GlobeNewswire
·
Nov 07, 2025

IRLAB’s Research Advances Highlighted at AD/PD 2026 Conference

TIPRANKS
·
Nov 07, 2025

Alector Reports Third Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire
·
Nov 07, 2025

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program

GlobeNewswire
·
Nov 05, 2025

Supernus Announces Third Quarter 2025 Financial Results

GlobeNewswire
·
Nov 05, 2025

Crescent Biopharma to Present Preclinical Data for CR-001, a PD-1 x VEGF Bispecific Antibody, at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting

GlobeNewswire
·
Nov 04, 2025

Certara Automates Scientific Workflows with Phoenix® Cloud

GlobeNewswire
·
Nov 04, 2025

Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Advance Phase 2 Clinical Trial of Dimeric Fc-modified anti-CD40L mAb, TNX-1500, to Prevent Kidney Transplant Organ Rejection

GlobeNewswire
·
Nov 04, 2025

Press Release: AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Dow Jones
·
Nov 04, 2025

CStone Pharmaceuticals-B (02616) Announces IND Approval in China for Phase II Clinical Trial of CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) Combination Therapy, Further Exploring Trispecific Antibody Potential

Stock News
·
Nov 04, 2025

ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

GlobeNewswire
·
Nov 04, 2025

Sunshine Guojian Pharmaceutical (688336.SH): Pfizer Registers Two Global Phase III Trials for PD-1/VEGF Bispecific Antibody PF-08634404 (SSGJ-707), Final Payment Remains Uncertain

Stock News
·
Nov 03, 2025

ABBISKO-B (02256) Completes First Patient Dosing in Phase II Clinical Trial of Oral Small-Molecule PD-L1 Inhibitor ABSK043 Combined with Golecerase for NSCLC Treatment

Stock News
·
Nov 03, 2025

Beta Bionics Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Guidance

GlobeNewswire
·
Oct 29, 2025

Press Release: Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules

Dow Jones
·
Oct 27, 2025

AACR Abstract: First Evidence that Selective A2B Receptor Inhibition Lowers PD-L1 Tumor Expression and also Directly Suppresses Mesothelioma Tumor Growth

GlobeNewswire
·
Oct 23, 2025

ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group

GlobeNewswire
·
Oct 22, 2025